Decoding 7 Analyst Evaluations For United Therapeutics
Portfolio Pulse from Benzinga Insights
In the past three months, 7 analysts have evaluated United Therapeutics (NASDAQ:UTHR), with a majority expressing bullish sentiments. Analysts have set a 12-month average price target of $409.57, reflecting an 18.57% increase from the previous target. The company has shown strong financial performance with a notable net margin and ROE, despite lagging revenue growth compared to peers.
October 21, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics has received predominantly bullish analyst ratings, with a 12-month average price target of $409.57, indicating an 18.57% increase. The company's strong net margin and ROE suggest robust financial health, although revenue growth lags behind industry peers.
The majority of analysts have given bullish ratings, and the average price target has increased significantly, suggesting positive sentiment. The company's strong financial metrics, such as net margin and ROE, further support a positive outlook. However, the lag in revenue growth compared to peers is a slight concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100